Condition: Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · Metastatic Hormone Sensitive Prostate Cancer · Sponsor: AdvanCell Pty Limited
This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of \[212Pb\]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D). The Phase 2a expansion aims to assess the efficacy and safety of \[212Pb\]Pb-ADVC001 at the RP2 doses in 3 participant groups.
This description comes directly from the study's public registry record.
Anna Karmann · 612 8000 4199 · contact@advancell.com.au
Always discuss trial participation with your own doctor first.
| Royal Brisbane & Women's Hospital | Brisbane, Queensland, Australia | Recruiting |
| Princess Alexandra Hospital | Brisbane, Queensland, Australia | Recruiting |
| Gold Coast University Hospital | Southport, Queensland, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05720130